Two Seas Capital LP has recently announced that it has increased stake in Esperion Therapeutics Inc. (NASDAQ:ESPR) by 160.79%. After grabbing 7.67 million shares, the institutional investor is now in possession of 4.73 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 6.75% having worth around $10.2 million. Moreover, Millennium Management LLC increased its share by 2.45 million to have a control over 5.79 million shares. And The Vanguard Group, Inc. raised its holdings to 0.48 million shares by acquiring 4.72 million shares or 4.15% of the stake.
Esperion Therapeutics Inc. (ESPR) concluded trading on 01/03/24 at a closing price of $2.30, with 17.35 million shares of worth about $39.92 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 47.44% during that period and on Wednesday the price saw a loss of about -21.23%. Currently the company’s common shares owned by public are about 113.72M shares, out of which, 112.81M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 9 analysts are covering the ESPR stock and their offered price forecasts bring an average price target of $8.25. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $22.00 and could fall to a lowest price of $2.00. The stock’s current price level is 71.46% above of average price target set by the analysts, while a rise to estimated low would result in loss of -15.0% for the stock. However, touching the estimated high of $22.00 would mean a gain of 89.55% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 33 times over the past 12 months. They bought 286,561 shares in 17 of the transactions. In 16 selling transactions, insiders dumped 37,542 shares.
Wasatch Ultra Growth Fund, BB Biotech AG, and Vanguard Total Stock Market ETF are the top 3 mutual funds which are holding stakes in Esperion Therapeutics Inc. Wasatch Ultra Growth Fund is currently holding 4.68 million shares of worth totaling $6.23 million. The company recently came buying 1.09 million shares which brought its stake up to 4.12% of the company’s outstanding shares. Vanguard Total Stock Market ETF, after buying 2.69 million shares, have now control over 2.37% of the stake in the company. It holds 0.0 shares of worth $3.58 million.
Esperion Therapeutics Inc. (NASDAQ: ESPR) started trading at $2.44, below -$0.48 from concluding price of the previous day. However, the stock later moved at a day high price of 2.4700, or with a loss of -21.23%. Stock saw a price change of -10.85% in past 5 days and over the past one month there was a price change of 59.72%. Year-to-date (YTD), ESPR shares are showing a performance of -23.08% which decreased to -63.08% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.70 but also hit the highest price of $7.41 during that period. The average intraday trading volume for Esperion Therapeutics Inc. shares is 4.41 million. The stock is currently trading 11.06% above its 20-day simple moving average (SMA20), while that difference is up 59.37% for SMA50 and it goes to 64.25% higher than SMA200.
Two Seas Capital LP acquired 7.67 million shares of Esperion Therapeutics Inc. having value of about $10.2 million. Data submitted at the U.S SEC by Two Seas Capital LP revealed that the firm now holds 4.73 million shares in the company valued at close to $10879685.4, or have control over 160.79% stake in the company. Esperion Therapeutics Inc. (NASDAQ: ESPR) currently have 113.72M outstanding shares and institutions hold larger chunk of about 78.03% of that. Holding of mutual funds in the company is about 19.92% while other institutional holders and individual stake holders have control over 53.27% and 14.03% of the stake respectively.
The stock has a current market capitalization of $261.56M and its 3Y-monthly beta is at 0.79. It has posted earnings per share of -$2.37 in the same period. It has Quick Ratio of 1.21. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ESPR, volatility over the week remained 15.00% while standing at 11.53% over the month.
Analysts are in expectations that Esperion Therapeutics Inc. (ESPR) stock would likely to be making an EPS of $Spirit Aerosystems Holdings, In in the current quarter, while forecast for next quarter EPS is $30.13 and it is $Stocks for next year. For the current quarter EPS, analysts have given the company a lowest target $EPR Properties which is $Express, Inc. at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $Jasper Therapeutics, Inc. in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 43.79% while it is estimated to increase by 98.27% in next year. EPS is likely to grow at an annualized rate of 16.90% for next 5-years, compared to annual growth of 12.80% made by the stock over the past 5-years.
Analysts at 9 brokerage firms have issued recommendations for the Esperion Therapeutics Inc. (ESPR)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.67. Out of those 9 Wall Street analysts, 7 recommended a “Buy” rating, while 2 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
